Induction of experimental allergic encephalomyelitis in a low-susceptible Albino Oxford rat strain by somatostatin analogue SMS 201-995

NeuroImmunoModulation

Volumn 12, Issue 1, 2005, Pages 20-28

  Muhvić, Damir ^a   Barac Latas, Vesna ^a   Rukavina, Daniel ^a   Radosevic Stasic, Biserka ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Experimental allergic encephalomyelitis; Experimental allergic encephalomyelitis resistant albino oxford rats; Octreotide; Somatostatin analogue 201 995

Indexed keywords

FREUND ADJUVANT; OCTREOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; ENCEPHALOMYELITIS; FLOW CYTOMETRY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, SURFACE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GASTROINTESTINAL AGENTS; GENETIC PREDISPOSITION TO DISEASE; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; OCTREOTIDE; RATS; RATS, INBRED STRAINS; SOMATOSTATIN; UP-REGULATION;

EID: 17244364037     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082361     Document Type: Article

References (57)

1. Hohlfeld R, Wekerle H: Immunological update on multiple sclerosis. Curr Opin Neurol 2001;14:299-304.
2. Hemmer B, Cepok S, Nessler S, Sommer N: Pathogenesis of multiple sclerosis: An update on immunology. Curr Opin Neurol 2002;15:227-231.
3. Petry KG, Boullerne AI, Pousset F, Brochet B, Caille JM, Dousset V: Experimental allergic encephalomyelitis animal models for analyzing features of multiple sclerosis. Pathol Biol (Paris) 2000;48:47-53.
4. Segal BM: Experimental autoimmune encephalomyelitis: Cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr Allergy Asthma Rep 2003;3:86-93.
5. Swanborg RH: Experimental autoimmune encephalomyelitis in the rat: Lessons in T-cell immunology and autoreactivity. Immunol Rev 2001;184:129-135.
6. Tabira T: Cellular and molecular aspects of the pathomechanism and therapy of murine experimental allergic encephalomyelitis. Crit Rev Neurobiol 1989;5:113-142.
7. Wick G, Sgonc R, Lechner O: Neuroendocrine-immune disturbances in animal models with spontaneous autoimmune diseases. Ann NY Acad Sci 1998;840:591-598.
8. Tsigos C, Chrousos GP: Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002;53:865-871.
9. Eskandari F, Sternberg EM: Neural-immune interactions in health and disease. Ann NY Acad Sci 2002;966:20-27.
10. Tonelli L, Webster JI, Rapp KL, Sternberg E: Neuroendocrine responses regulating susceptibility and resistance to autoimmune/inflammatory disease in inbred rat strains. Immunol Rev 2001;184:203-211.
11. Prat A, Antel JP: Neuroendocrine influences on autoimmune diseases: Multiple sclerosis; in Ader R, Felten DL, Cohen N (ed): Psychoneuroimmunology, ed 3. San Diego, Academic, 2001, vol 2, pp 433-449.
12. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP: Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991;254:421-423.
13. Karalis K, Muglia LJ, Bae D, Hilderbrand H, Majzoub JA: CRH and the immune system. J Neuroimmunol 1997;72:131-136.
14. Mason D, MacPhee I, Antoni F: The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. Immunology 1990;70:1-5.
15. Maron R, Hancock WW, Slavin A, Hattori M, Kuchroo V, Weiner HL: Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. Int Immunol 1999;11:1573-1580.
16. Sternberg EM, Young WS 3rd, Bernardini R, Calogero AE, Chrousos GP, Gold PW, Wilder RL: A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989;86:4771-4775.
17. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, Wilder RL: Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 1989;86:2374-2378.
18. Crofford LJ, Sano H, Karalis K, Webster EL, Goldmuntz EA, Chrousos GP, Wilder RL: Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. J Clin Invest 1992;90:2555-2564.
19. Vukmanovic S, Stojkovic MM, Lukic ML: Experimental autoimmune encephalomyelitis in 'low' and 'high' interleukin 2 producer rats. I. Cellular basis of induction. Cell Immunol 1989;121:237-246.
20. Mostarica-Stojkovic M, Vukmanovic S, Ramic Z, Lukic ML: Evidence for target tissue regulation of resistance to the induction of experimental allergic encephalomyelitis in AO rats. J Neuroimmunol 1992;41:97-104.
21. Muhvic D, Radosevic-Stasic B, Pugel E, Rukavina D, Sepcic J, Efendic S: Modulation of experimental allergic encephalomyelitis by somatostatin. Ann NY Acad Sci 1992;650:170-178.
22. Sorensen KV: Somatostatin in multiple sclerosis. Acta Neurol Scand 1987;75:161-167.
23. Vecsei L, Csala B, Widerlov E, Ekman R, Czopf J, Palffy G: Lumbar cerebrospinal fluid concentrations of somatostatin and neuropeptide Y in multiple sclerosis. Brain Res Bull 1990;25:411-413.
24. Vecsei L, Widerlov E: Preclinical and clinical studies with somatostatin related to the central nervous system. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:473-502.
25. Roca CA, Su TP, Elpern S, McFarland H, Rubinow DR: Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis. Biol Psychiatry 1999;46:551-556.
26. Maeda K, Yasuda M, Kaneda H, Maeda S, Yamadori A: Cerebrospinal fluid (CSF) neuropeptide Y- and somatostatin-like immunoreactivities in man. Neuropeptides 1994;27:323-332.
27. Epelbaum J, Doumaud P, Fodor M, Viollet C: The neurobiology of somatostatin. Crit Rev Neurobiol 1994;8:25-44.
28. Krantic S: Peptides as regulators of the immune system: Emphasis on somatostatin. Peptides 2000;21:1941-1964.
29. Krulich I, Dharwal AP, McCann SM: Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968;83:783-790.
30. Vale W, Brazeau P, Rivier C, Brown M, Boss B, Rivier J, Burgus R, Ling N, Guillemin R: Somatostatin. Recent Prog Horm Res 1975;31:365-397.
31. Efendic S, Hokfelt T, Luft R: Somatostatin. Adv Metab Disord 1978;9:367-424.
32. Brazeau P: Somatostatin: A peptide with unexpected physiologic activities. Am J Med 1986;81:8-13.
33. Lamberts SW, Zuyderwijk J, den Holder F, van Koetsveld P, Hofland L: Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 1989;50:44-50.
34. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-198.
35. Karalis K, Mastorakos G, Sano H, Wilder RL, Chrousos GP: Somatostatin may participate in the antiinflammatory actions of glucocorticoids. Endocrinology 1995;136:4133-4138.
36. Karalis K, Mastorakos G, Chrousos GP, Tolis G: Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994;93:2000-2006.
37. Payan DG, McGillis JP, Goetzl EJ: Neuroimmunology. Adv Immunol 1986;39:299-323.
38. Hofland LJ, van Hagen PM, Lamberts SW: Functional role of somatostatin receptors in neuroendocrine and immune cells. Ann Med 1999;31(suppl 2):23-27.
39. Lichtenauer-Kaligis EG, van Hagen PM, Lamberts SW, Hofland LJ: Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 2000;143:S21-S25.
40. ten Bokum AM, Hofland LJ, van Hagen PM: Somatostatin and somatostatin receptors in the immune system: A review. Eur Cytokine Netw 2000;11:161-176.
41. Polic L, Radosevic-Stasic B, Rukavina D, Efendic S: Humoral immune response of mice and rats treated with somatostatin. Period Biol 1982;85:101-102.
42. Radosevic-Stasic B, Polic L, Rukavina D, Efendic S: Inhibition of local graft-versus-host reaction by somatostatin in mice. IRCS Med Sci 1983;11:1097.
43. Radosevic-Stasic B, Trobonjaca Z, Lucin P, Cuk M, Polic B, Rukavina D: Immunosuppressive and antiproliferative effects of somatostatin analog SMS 201-995. Int J Neurosci 1995;81:283-297.
44. Ganea D, Delgado M: Inhibitory neuropeptide receptors on macrophages. Microbes Infect 2001;3:141-147.
45. Lattuada D, Casnici C, Venuto A, Marelli O: The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes. J Neuroimmunol 2002;133:211-216.
46. Chao TC, Cheng HP, Walter RJ: Somatostatin and macrophage function: Modulation of hydrogen peroxide, nitric oxide and tumor necrosis factor release. Regul Pept 1995;58:1-10.
47. Peluso G, Petillo O, Melone MA, Mazzarella G, Ranieri M, Tajana GF: Modulation of cytokine production in activated human monocytes by somatostatin. Neuropeptides 1996;30:443-451.
48. Chowers Y, Cahalon L, Lahav M, Schor H, Tal R, Bar-Meir S, Levite M: Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol 2000;165:2955-2961.
49. Bellocq A, Doublier S, Suberville S, Perez J, Escoubet B, Fouqueray B, Puyol DR, Baud L: Somatostatin increases glucocorticoid binding and signaling in macrophages by blocking the calpain-specific cleavage of Hsp 90. J Biol Chem 1999;274:36891-36896.
50. Ghamrawy CE, Rabourdin-Combe C, Krantic S: sst5 somatostatin receptor mRNA induction by mitogenic activation of human T-lymphocytes. Peptides 1999;20:305-311.
51. Solomou K, Ritter MA, Palmer DB: Somatostatin is expressed in the murine thymus and enhances thymocyte development. Eur J Immunol 2002;32:1550-1559.
52. ten Bokum AM, Rosmalen JG, Hofland LJ, Krenning EP, Van Hagen PM, Breeman WA: Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity. Nucl Med Commun 2002;23:1009-1017.
53. Correale J, Arias M, Gilmore W: Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 1998;161:3365-3374.
54. Schwartz M: Beneficial autoimmune T cells and posttraumatic neuroprotection. Ann NY Acad Sci 2000;917:341-347.
55. Schwartz M, Moalem G: Beneficial immune activity after CNS injury: Prospects for vaccination. J Neuroimmunol 2001;113:185-192.
56. Hammond KJL, Godfrey DI: NKT cells: Potential targets for autoimmune disease therapy? Tissue Antigens 2002;59:353-363.
57. Levite M: Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. Proc Natl Acad Sci USA 1998;95:12544-12549.